Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Jun 7:14:1182644.
doi: 10.3389/fphar.2023.1182644. eCollection 2023.

Comparison of bleeding risk and hypofibrinogenemia-associated risk factors between tigecycline with cefoperazone/sulbactam therapy and other tigecycline-based combination therapies

Lei Zhang  1 , Xinfeng Cai  2 , Fangchen Peng  1 , Shuangshuang Tian  3 , Xinjing Wu  4 , Yun Li  1 , Jinlin Guo  1
Affiliations

Comparison of bleeding risk and hypofibrinogenemia-associated risk factors between tigecycline with cefoperazone/sulbactam therapy and other tigecycline-based combination therapies

Lei Zhang et al. Front Pharmacol. .

Erratum in

Abstract

Background: Tigecycline and cefoperazone/sulbactam can cause coagulation disorders; tigecycline may also lead to hypofibrinogenemia, raising safety concerns. This study aimed to investigate whether tigecycline plus cefoperazone/sulbactam increases the risk of bleeding compared with other tigecycline-based combination therapies and identify risk factors for tigecycline-associated hypofibrinogenemia. Methods: In this multi-method, multicenter, retrospective study, coagulation and other baseline variables were compared using a cohort study, and risk factors for hypofibrinogenemia using a case-control study. Results: The 451 enrolled participants were divided into three group: tigecycline plus cefoperazone/sulbactam (Group A, 193 patients), tigecycline plus carbapenems (Group B, 200 patients) and tigecycline plus β-lactams without N-methylthio-tetrazole (NMTT) side chains (Group C, 58 patients). Activated partial thromboplastin time and prothrombin time were prolonged, and fibrinogen declined for all patients after tigecycline-based medication (all p < 0.05). Prothrombin time in Group B was significantly longer than in other groups (p < 0.05), but there were no significant differences in bleeding events between the three groups (p = 0.845). Age greater than 80 years (OR: 2.85, 95% CI: 1.07-7.60), treatment duration (OR: 1.29, 95% CI: 1.19-1.41), daily dose (OR: 2.6, 95% CI: 1.29-5.25), total bilirubin (OR: 1.01, 95% CI: 1.01-1.02) and basal fibrinogen (OR: 1.32, 95% CI: 1.14-1.63) were independent risk factors of hypofibrinogenemia. The optimal cut-off for treatment course was 6 days for high-dose and 11 days for low-dose. Conclusion: Tigecycline plus cefoperazone/sulbactam did not increase the risk of bleeding compared with tigecycline plus carbapenem, or tigecycline plus β-lactam antibiotics without NMTT-side-chains. Coagulation function should be closely monitored in patients receiving tigecycline treatment.

Keywords: carbapenems; cefoperazone/sulbactam; coagulation disorders; hypofibrinogenaemia; tigecycline; β-lactam antibiotics.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Cai Z., Yang W., He Y., Chen Q., Wang S., Luo X., et al. (2016). Cefoperazone/sulbactam-induced abdominal wall hematoma and upper gastrointestinal bleeding: A case report and review of the literature. Drug Saf. Case Rep. 3 (1), 2. 10.1007/s40800-016-0025-9 - DOI - PMC - PubMed
    1. Campany-Herrero D., Larrosa-Garcia M., Lalueza-Broto P., Rivera-Sánchez L., Espinosa-Pereiro J., Mestre-Torres J., et al. (2020). Tigecycline-associated hypofibrinogenemia in a real-world setting. Int. J. Clin. Pharm. 42 (4), 1184–1189. 10.1007/s11096-020-01072-7 - DOI - PubMed
    1. Chen L. J., Hsiao F. Y., Shen L. J., Wu F. L. L., Tsay W., Hung C. C., et al. (2016). Use of hypoprothrombinemia-inducing cephalosporins and the risk of hemorrhagic events: A nationwide nested case-control study. PLoS One 11 (7), e0158407. 10.1371/journal.pone.0158407 - DOI - PMC - PubMed
    1. Conly J. M., Stein K. (1992). The production of menaquinones (vitamin K2) by intestinal bacteria and their role in maintaining coagulation homeostasis. Prog. Food Nutr. Sci. 16 (4), 307–343. - PubMed
    1. Cui N., Cai H., Li Z., Lu Y., Wang G., Lu A. (2019). Tigecycline-induced coagulopathy: A literature review. Int. J. Clin. Pharm. 41 (6), 1408–1413. 10.1007/s11096-019-00912-5 - DOI - PubMed

LinkOut - more resources